214337-35-6

Upstream product

• 540-80-7 tert.-butylnitrite 
• 13797-77-8 5-methoxythiazolo[5,4-b]pyridin-2-amine 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 

Downstream Products

• 1415798-36-5 N-(4-(2-amino-3-chloropyridine-4-oxy)-3-fluorophenyl)-2-(dimethylamino)-4-(4-fluorophenyl)-5-oxo-4,5-dihydro-thiazolo[5,4-b]pyridine-6-formamide 
• 1415797-93-1 2-(dimethylamino)-4-(4-fluorophenyl)-5-oxo-4,5-dihydrothiazolo[5,4-b]pyridine-6-formic acid 
• 1415797-92-0 methyl 2-(dimethylamino)-4-(4-fluorophenyl)-5-oxo-4,5-dihydrothiazolo[5,4-b]pyridine-6-formate 

Relevant academic research and scientific papers

PYRIDINIUM DERIVATIVES AS HERBICIDES

Compounds of the formula (I) (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

NOVEL COMPOUNDS

The invention is directed to certain novel compounds. Specifically, the invention directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.